Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2007 2
2011 2
2012 2
2013 2
2015 1
2017 2
2019 1
2020 3
2021 2
2022 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial.
Sahni J, Patel SS, Dugel PU, Khanani AM, Jhaveri CD, Wykoff CC, Hershberger VS, Pauly-Evers M, Sadikhov S, Szczesny P, Schwab D, Nogoceke E, Osborne A, Weikert R, Fauser S. Sahni J, et al. Ophthalmology. 2019 Aug;126(8):1155-1170. doi: 10.1016/j.ophtha.2019.03.023. Epub 2019 Mar 21. Ophthalmology. 2019. PMID: 30905643 Free article. Clinical Trial.
Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial.
Khanani AM, Patel SS, Ferrone PJ, Osborne A, Sahni J, Grzeschik S, Basu K, Ehrlich JS, Haskova Z, Dugel PU. Khanani AM, et al. Among authors: sahni j. JAMA Ophthalmol. 2020 Sep 1;138(9):964-972. doi: 10.1001/jamaophthalmol.2020.2699. JAMA Ophthalmol. 2020. PMID: 32729897 Free PMC article. Clinical Trial.
Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial.
Sahni J, Dugel PU, Patel SS, Chittum ME, Berger B, Del Valle Rubido M, Sadikhov S, Szczesny P, Schwab D, Nogoceke E, Weikert R, Fauser S. Sahni J, et al. JAMA Ophthalmol. 2020 Sep 1;138(9):955-963. doi: 10.1001/jamaophthalmol.2020.2685. JAMA Ophthalmol. 2020. PMID: 32729888 Free PMC article. Clinical Trial.
Deliberations of an International Panel of Experts on OCT Angiography Nomenclature of Neovascular Age-Related Macular Degeneration.
Mendonça LSM, Perrott-Reynolds R, Schwartz R, Madi HA, Cronbach N, Gendelman I, Muldrew A, Bannon F, Balaskas K, Gemmy Cheung CM, Fawzi A, Ferrara D, Freund KB, Fujimoto J, Munk MR, Querques G, Ribeiro R, Rosenfeld PJ, Sadda SR, Sahni J, Sarraf D, Spaide RF, Schmidt-Erfurth U, Souied E, Staurenghi G, Tadayoni R, Wang RK, Chakravarthy U, Waheed NK. Mendonça LSM, et al. Among authors: sahni j. Ophthalmology. 2021 Jul;128(7):1109-1112. doi: 10.1016/j.ophtha.2020.12.022. Epub 2020 Dec 25. Ophthalmology. 2021. PMID: 33359557 Free article. Review. No abstract available.
QUANTITATIVE ASSESSMENT OF AUTOMATED OPTICAL COHERENCE TOMOGRAPHY IMAGE ANALYSIS USING A HOME-BASED DEVICE FOR SELF-MONITORING NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Oakley JD, Verdooner S, Russakoff DB, Brucker AJ, Seaman J, Sahni J, Bianchi CD, Cozzi M, Rogers J, Staurenghi G. Oakley JD, et al. Among authors: sahni j. Retina. 2023 Mar 1;43(3):433-443. doi: 10.1097/IAE.0000000000003677. Epub 2022 Nov 18. Retina. 2023. PMID: 36705991 Free PMC article.
Epimacular brachytherapy for previously treated neovascular age-related macular degeneration: month 36 results of the MERLOT randomised controlled trial.
Jackson TL, Soare C, Petrarca C, Simpson A, Neffendorf JE, Petrarca R, Muldrew KA, Peto T, Chakravarthy U, Membrey L, Haynes R, Costen M, Steel DHW, Desai R; MERLOT Study Group. Jackson TL, et al. Br J Ophthalmol. 2023 Jul;107(7):987-992. doi: 10.1136/bjophthalmol-2021-320620. Epub 2022 Feb 25. Br J Ophthalmol. 2023. PMID: 35217515 Clinical Trial.
20 results